StageBio is excited to celebrate Dr. Stephanie Shrader in her new position as Vice President of Pathology Solutions.

Dr. Shrader has been with StageBio since 2019 and served as the General Toxicologic Pathology Director since 2022. With a particular interest in ocular pathology, she brings her expertise in the evaluation of numerous ophthalmic drugs, animal models, ocular administration routes, and ocular medical devices to the role. In her new role, Dr. Shrader will continue to lead StageBio’s successful ocular service line. 

Over the course of her career, Dr. Shrader has collaborated on extramural research projects, authored peer-reviewed manuscripts and book chapters, and has served as a reviewer for multiple medical journals. 

On her new position with StageBio, Kimberly Uptgraft, Senior VP, Operations remarks, “Dr Shrader’s leadership will undoubtedly contribute to the continued success of our Pathology Solutions team and bring a bright future for StageBio and the clients we serve.” 

Congratulations, Dr Shrader! We look forward to all you will accomplish in your new role. Learn more about Dr Shrader in this spotlight, or to learn more about the StageBio team, go here. 

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for the biopharmaceutical, medical device, academic, government and contract research industries. The company operates four GLP laboratories as well as two GLP specimen archiving facilities in the U.S. and Europe, with substantial continued investment in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30 board-certified veterinary pathologists and more than 100 laboratory personnel on staff supporting our unified commitment to quality, scientific integrity and client satisfaction. Learn more at www.stagebio.com.

About Dr Stephanie Shrader: 

Dr. Stephanie Shrader joined the StageBio team as a Senior Pathologist in 2019, where she grew to become the General Toxicologic Pathology Director since 2022. She has a strong background and primary subspecialty interest in ocular pathology with extensive experience evaluating a variety of ophthalmic drugs, animal models, ocular dosing routes, and ocular medical devices. Prior to StageBio, Dr. Shrader spent two years at Charles River Laboratories in Spencerville, Ohio where she also served as the site’s IACUC chairperson. She is an active member of the American College of Veterinary Pathologists (ACVP) and the Society of Toxicologic Pathology (STP), enjoys collaborating with her colleagues to author book chapters and peer reviewed journal articles, and serves as a peer reviewer for several journals. Dr. Shrader earned a BS in Biological Sciences from Wilson College in Pennsylvania, a DVM from the Virginia-Maryland College of Veterinary Medicine and completed her anatomic pathology residency and PhD in Biomedical Sciences at the Auburn University College of Veterinary Medicine. Stephanie resides in Delphos, Ohio with her husband, Jeff, and their canine companions.